163 related articles for article (PubMed ID: 37503763)
1. Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes.
Park S; Jeong HE; Bea S; Yu OHY; Cho YM; You SC; Man KKC; Shin JY
Diabetes Obes Metab; 2023 Nov; 25(11):3248-3258. PubMed ID: 37503763
[TBL] [Abstract][Full Text] [Related]
2. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
[TBL] [Abstract][Full Text] [Related]
3. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
4. Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.
Melzer Cohen C; Schechter M; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Fishkin A; Rosenzweig D; Chodick G; Karasik A; Mosenzon O
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1153-1162. PubMed ID: 37382938
[TBL] [Abstract][Full Text] [Related]
5. Association Between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients With Type 2 Diabetes.
Au PCM; Tan KCB; Cheung BMY; Wong ICK; Wong Y; Cheung CL
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1719-e1726. PubMed ID: 34748021
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review.
Yang CT; Peng ZY; Chen YC; Ou HT; Kuo S
Front Endocrinol (Lausanne); 2022; 13():836365. PubMed ID: 35330915
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M
Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547
[TBL] [Abstract][Full Text] [Related]
8. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
9. Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes.
Au PCM; Tan KCB; Cheung BMY; Wong ICK; Li HL; Cheung CL
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2962-e2970. PubMed ID: 35303075
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature review.
Peng ZY; Yang CT; Ou HT; Kuo S
Diabetes Obes Metab; 2022 Jul; 24(7):1328-1337. PubMed ID: 35373898
[TBL] [Abstract][Full Text] [Related]
11. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.
Du Y; Bai L; Fan B; Ding H; Ding H; Hou L; Ma H; Xing N; Wang F
Prim Care Diabetes; 2022 Feb; 16(1):156-161. PubMed ID: 34930687
[TBL] [Abstract][Full Text] [Related]
12. Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan.
Mizutani G; Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2022 Dec; 13(12):2000-2009. PubMed ID: 36124433
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Han SJ; Ha KH; Lee N; Kim DJ
Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
[TBL] [Abstract][Full Text] [Related]
15. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors.
Zerovnik S; Kos M; Locatelli I
Acta Diabetol; 2022 Feb; 59(2):233-241. PubMed ID: 34609620
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter-2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes.
Fujita KK; Ye F; Collister D; Klarenbach S; Campbell DJT; Chew DS; Quinn AE; Ronksley P; Lau D
Diabetes Obes Metab; 2024 Feb; 26(2):699-709. PubMed ID: 37997302
[TBL] [Abstract][Full Text] [Related]
17. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S; Lam CSP; Kim DJ; Cavender MA; Norhammar A; Jørgensen ME; Birkeland KI; Holl RW; Franch-Nadal J; Tangri N; Shaw JE; Ilomäki J; Karasik A; Goh SY; Chiang CE; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P; Kosiborod M;
Lancet Diabetes Endocrinol; 2020 Jul; 8(7):606-615. PubMed ID: 32559476
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease.
Rhee JJ; Han J; Montez-Rath ME; Kim SH; Cullen MR; Stafford RS; Winkelmayer WC; Chertow GM
Diabetes Obes Metab; 2022 May; 24(5):928-937. PubMed ID: 35118793
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
20. Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes - exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations.
Alshnbari A; Alkharaiji M; Anyanwagu U; Idris I
Curr Med Res Opin; 2020 Dec; 36(12):1985-1989. PubMed ID: 33085525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
